Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial
Executive Summary
Restrictive risk management plan for antidepressant nasal spray requires patients be monitored for two hours after dosing and enroll in a patient registry; Janssen has agreed to conduct a monotherapy efficacy trial as a postmarketing commitment.
You may also be interested in...
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
Last-Minute Pushback On Janssen’s EU Spravato Approval
What is in store for esketamine after third parties submit written interventions to the European Medicines Agency?